Publications by authors named "I De Benedetto"
Chagas disease, vectored by kissing bugs, poses a public health problem across the Americas. The best way for reducing disease transmission is through vector control, which is currently based on the use of insecticides. However, insecticide resistance, and environmental and health issues, stress the need for new, environmentally-friendly methods for reducing vector-host contacts.
View Article and Find Full Text PDFArticle Synopsis
- Meropenem-vaborbactam is a new treatment option for infections caused by KPC-producing Klebsiella pneumoniae, particularly those resistant to ceftazidime-avibactam.
- A study of 342 patients across 19 hospitals in Italy evaluated the outcomes of those treated with meropenem-vaborbactam, finding a 30-day mortality rate of 31.6%.
- The research identified risk factors for higher mortality, including septic shock, significant comorbidities, and delayed treatment, while the administration of the drug within 48 hours of infection onset was linked to better outcomes.
A 30-year-old White woman with presumed rheumatoid arthritis accompanied by CT scan evidence of eosinophilic pneumonitis was referred to the ED by her rheumatologist for an investigation of the progression of dyspnea. Approximately 6 months before, the patient reported experiencing diffuse interphalangeal arthralgias (both proximal and distal) that affected the wrists, knees, and feet. These symptoms were accompanied by Modified Medical Research Council scale grade 2 dyspnea.
View Article and Find Full Text PDFCeftobiprole is a fifth-generation cephalosporin approved by European and American regulatory agencies for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Ceftobiprole administration is useful in severe CAP as well as HAP where the potential is to save other β-lactams including carbapenems or linezolid/vancomycin in clinical practice. The aim of this study was to report the real-world evidence of ceftobiprole in patients with CAP and HAP in a single center.
View Article and Find Full Text PDFArticle Synopsis
- Left ventricular assist devices (LVADs) are increasingly used to treat end-stage heart failure, but they often lead to long-term complications, particularly infections and coagulation issues.
- In a study involving 64 patients who received LVADs, about 50% experienced nosocomial infections (NIs), mainly related to the devices, with significant involvement of gram-negative bacteria and multidrug-resistant strains.
- Key risk factors for infections included length of ICU stay and patient classification, with no significant differences in mortality rates between infected and non-infected patients.